In 2013, the FDA warned the general public about the dangers of Benicar
and required its manufacturers to update the warning label. These dangers
included developing a serous GI disorder, known as sprue-like enteropathy,
which can lead to severe malnutrition, diarrhea, and dehydration. Now,
injured patients are beginning to file lawsuits across the country, seeking
to hold the negligent pharmaceutical manufacturer responsible for their
In 2013, the FDA began to investigate the link between Benicar and sprue-like
enteropathy after a 2012 study by the Mayo Clinic exposed the connection.
This led to the FDA forcing Benicar’s manufacturer to update Benicar’s
labels warning patients of the serious gastrointestinal risks associated
with using their drug.
Unfortunately, Benicar-induced sprue-like enteropathy may have affected
more people than the manufacturers realize. Since sprue-like enteropathy
caused by Benicar is similar to Celiac disease and gluten intolerance,
many individuals may have been mistakenly diagnosed with Celiac disease
or may be trying to control their GI symptoms with over-the-counter medications
and/or a gluten-free diet.
The complications that can arise from Benicar-induced sprue-like enteropathy
is staggering. Patients have reported years of diarrhea and malnutrition
that has caused long-term intestinal damage in many. This can eventually
lead to fatal GI complications if not treated quickly.
First Benicar Lawsuit Filed
The first Benicar lawsuit was filed earlier this year when a Texas man
claimed that he developed severe gastrointestinal symptoms, including
malnutrition and severe diarrhea after using Benicar. Due to his Benicar-induced
illness, he was forced to spend over 100 days in the hospital and must
now be fed through a feeding tube.
Several other plaintiffs have already come forward and filed the first
of many Benicar lawsuits, alleging that the drug manufacturer failed to
adequately warn the public of the dangers associated with the use of Benicar
for hypertension. In addition, those lawsuits allege that the company
knew of these risks and still promoted their drug without updating the labels.
This isn’t the first time Benicar manufacturer Daiichi Sankyo has
been in trouble with the FDA. In 2006, the FDA accused the company of
deliberately and fraudulently marketing Benicar, by using false and unsubstantiated
statements that failed to include important Benicar health risk information.
In 2013, the FDA also cited the Benicar manufacturer for direct mail ads
that made misleading and unsubstantiated claims to patients.